Infectious Bursal Disease Virus antigenic isolates and vaccines

Abstract

Antigenic isolates and vaccines for Infectious Bursal Disease Virus include variants of the molecular Group 6 family of IBDV isolates, in particular the 28-1 isolate.

1 - 18 . (canceled) 
     
     
         19 . An Infectious Bursal Disease Virus (IBDV) Viral Protein-2 (VP-2) antigen comprising the amino acid sequence of SEQ ID NO:1 and further comprising two or more amino acid substitutions,
 wherein the first amino acid substitution is G to D at amino acid position 318 and wherein said first amino acid substitution is the only amino acid substitution within the major hydrophilic peak B of the VP-2 amino acid sequence, and   wherein the second amino acid substitution is 254-N.   
     
     
         20 . A vaccine composition comprising the IBDV VP-2 antigen of  claim 19 . 
     
     
         21 . The vaccine composition of  claim 20 , further comprising a pharmacologically acceptable carrier. 
     
     
         22 . The vaccine composition of  claim 21 , wherein said carrier is an aqueous carrier. 
     
     
         23 . The vaccine of  claim 21 , wherein said carrier is an emulsion. 
     
     
         24 . The vaccine of  claim 22 , wherein said emulsion is a water-in-oil emulsion. 
     
     
         25 . The vaccine composition of  claim 20 , further comprising at least one additional vaccine antigen. 
     
     
         26 . The vaccine composition of  claim 25 , wherein said at least one additional vaccine antigen is selected from the group consisting of chicken herpes virus antigens, chicken anemia virus (CAV) antigens, Newcastle Disease virus antigens, Infectious Bronchitis (IB) virus antigens, reovirus antigens, and Infectious Bursal Disease Virus (IBDV) variant antigens. 
     
     
         27 . A method for inducing protection against infection from Infectious Bursal Disease Virus, said method comprising administering to a poultry animal the vaccine composition of  claim 20 . 
     
     
         28 . The method of  claim 27 , wherein said vaccine is administered to said poultry animal in ovo. 
     
     
         29 . The method of  claim 27 , wherein said poultry animal is a young post-hatch chick. 
     
     
         30 . An Infectious Bursal Disease virus comprising a Viral Protein-2 (VP-2), wherein said VP-2 comprises the amino acid sequence of SEQ ID NO:1 and further comprising two or more amino acid substitutions,
 wherein the first amino acid substitution is G to D at amino acid position 318 and wherein said first amino acid substitution is the only amino acid substitution within the major hydrophilic peak B of the VP-2 amino acid sequence, and   wherein the second amino acid substitution is 254-N.   
     
     
         31 . A vaccine composition comprising the Infectious Bursal Disease virus of  claim 30  and a pharmacologically acceptable carrier. 
     
     
         32 . The vaccine composition of  claim 31 , wherein said Infectious Bursal Disease virus is a live virus. 
     
     
         33 . The vaccine composition of  claim 32 , wherein said Infectious Bursal Disease virus is a live-attenuated virus. 
     
     
         34 . The vaccine composition of  claim 33 , wherein said live-attenuated virus has been serially passaged. 
     
     
         35 . The vaccine composition of  claim 31 , wherein said Infectious Bursal Disease virus is a killed-inactivated virus. 
     
     
         36 . The vaccine composition of  claim 31 , wherein said carrier is an aqueous carrier. 
     
     
         37 . The vaccine composition of  claim 31 , wherein said carrier is an emulsion. 
     
     
         38 . The vaccine composition of  claim 37 , wherein said emulsion is a water-in-oil emulsion.